Raphael Mwangi
YOU?
Author Swipe
View article: Development and Validation of a Gene Expression Signature to Predict Early Events in Patients with Follicular Lymphoma
Development and Validation of a Gene Expression Signature to Predict Early Events in Patients with Follicular Lymphoma Open
Although follicular lymphoma (FL) typically follows an indolent course, patients with FL who experience early events such as transformation or progression have increased risk of death related to lymphoma. The FL24Cx is an algorithm based o…
View article: Incidental vs. symptomatic diagnosis of follicular lymphoma: implications of earlier detection
Incidental vs. symptomatic diagnosis of follicular lymphoma: implications of earlier detection Open
Follicular lymphoma (FL) is usually diagnosed at an advanced stage when the patient presents with a palpable lymph node or symptoms such as pain and fatigue. However, due to advances in imaging techniques used for many diseases and cancer …
View article: An Individualized Prediction Model for Early-Stage Classic Hodgkin’s Lymphoma
An Individualized Prediction Model for Early-Stage Classic Hodgkin’s Lymphoma Open
Utilizing objective, continuous, and readily available variables, we developed and validated a new prediction model for early-stage cHL. Male sex, lower hemoglobin or albumin levels, and higher MTDs were associated with worse PFS. (Funded …
View article: 126 | THE EARLY‐STAGE CLASSIC HODGKIN LYMPHOMA INTERNATIONAL PROGNOSTICATION INDEX (E‐HIPI): AN INDIVIDUALIZED PREDICTION MODEL UTILIZING OBJECTIVE AND CONTINUOUS VARIABLES
126 | THE EARLY‐STAGE CLASSIC HODGKIN LYMPHOMA INTERNATIONAL PROGNOSTICATION INDEX (E‐HIPI): AN INDIVIDUALIZED PREDICTION MODEL UTILIZING OBJECTIVE AND CONTINUOUS VARIABLES Open
View article: 224 | REGULAR ASPIRIN USE PRIOR TO DIAGNOSIS AND FOLLICULAR LYMPHOMA PROGNOSIS: NOVEL ASSOCIATION WITH SUPERIOR EVENT‐FREE SURVIVAL
224 | REGULAR ASPIRIN USE PRIOR TO DIAGNOSIS AND FOLLICULAR LYMPHOMA PROGNOSIS: NOVEL ASSOCIATION WITH SUPERIOR EVENT‐FREE SURVIVAL Open
View article: 307 | IMPACT OF CELL OF ORIGIN, GENE REARRANGEMENTS, FRONTLINE TREATMENT ON INCIDENCE OF CENTRAL NERVOUS SYSTEM LYMPHOMA RELAPSE IN NEWLY DIAGNOSED LARGE B‐CELL LYMPHOMA
307 | IMPACT OF CELL OF ORIGIN, GENE REARRANGEMENTS, FRONTLINE TREATMENT ON INCIDENCE OF CENTRAL NERVOUS SYSTEM LYMPHOMA RELAPSE IN NEWLY DIAGNOSED LARGE B‐CELL LYMPHOMA Open
View article: 122 | IDENTIFYING HARMFUL HYPERINFLAMMATION IN DIFFUSE LARGE B‐CELL LYMPHOMA USING THE OHI (OPTIMIZED HLH INFLAMMATORY) INDEX—DISCOVERY AND VALIDATION IN REAL‐WORLD PATIENTS
122 | IDENTIFYING HARMFUL HYPERINFLAMMATION IN DIFFUSE LARGE B‐CELL LYMPHOMA USING THE OHI (OPTIMIZED HLH INFLAMMATORY) INDEX—DISCOVERY AND VALIDATION IN REAL‐WORLD PATIENTS Open
View article: Risk of lymphoid malignancy associated with cancer predisposition genes
Risk of lymphoid malignancy associated with cancer predisposition genes Open
View article: Comparison of outcomes in postinduction strategies for primary central nervous system lymphoma: a Mayo Clinic experience
Comparison of outcomes in postinduction strategies for primary central nervous system lymphoma: a Mayo Clinic experience Open
Primary central nervous system lymphoma (PCNSL) is a rare form of non-Hodgkin lymphoma involving the brain, cerebrospinal fluid, or retina/vitreous without systemic involvement. Induction with high-dose methotrexate (HD-MTX) followed by co…
View article: The A-HIPI prediction model in advanced-stage Hodgkin lymphoma: identification of risk groups and creation of an online tool
The A-HIPI prediction model in advanced-stage Hodgkin lymphoma: identification of risk groups and creation of an online tool Open
No abstract available
View article: Characteristics and outcomes of incidentally diagnosed diffuse large B‐cell lymphoma and implications for cancer screening
Characteristics and outcomes of incidentally diagnosed diffuse large B‐cell lymphoma and implications for cancer screening Open
Differences in characteristics and outcomes between incidental and symptomatic presentations of Large B-Cell Lymphoma.
View article: Evaluating the impact of laboratory-based eligibility criteria by race/ethnicity in first-line clinical trials of DLBCL
Evaluating the impact of laboratory-based eligibility criteria by race/ethnicity in first-line clinical trials of DLBCL Open
Underrepresentation of racial and ethnic subgroups in cancer clinical trials remains a persistent challenge. Restrictive clinical trial eligibility criteria have been shown to exacerbate this problem. We previously identified that up to 24…
View article: Multiomic analysis identifies a high-risk signature that predicts early clinical failure in DLBCL
Multiomic analysis identifies a high-risk signature that predicts early clinical failure in DLBCL Open
View article: Defining primary refractory large B-cell lymphoma
Defining primary refractory large B-cell lymphoma Open
Patients with large B-cell lymphoma (LBCL) that fail to achieve a complete response (CR) or who relapse early after anthracycline-containing immunochemotherapy (IC) have a poor prognosis and are commonly considered to have “primary refract…
View article: Marginal zone lymphoma international prognostic index: a unifying prognostic index for marginal zone lymphomas requiring systemic treatment
Marginal zone lymphoma international prognostic index: a unifying prognostic index for marginal zone lymphomas requiring systemic treatment Open
View article: Beyond Atrial Fibrillation: Machine Learning Algorithm Predicts Stroke in Adult Patients With Congenital Heart Disease
Beyond Atrial Fibrillation: Machine Learning Algorithm Predicts Stroke in Adult Patients With Congenital Heart Disease Open
View article: Evaluation of clinical parameters and biomarkers in older, untreated mantle cell lymphoma patients receiving <scp>bendamustine–rituximab</scp>
Evaluation of clinical parameters and biomarkers in older, untreated mantle cell lymphoma patients receiving <span>bendamustine–rituximab</span> Open
Summary Mantle cell lymphoma (MCL) is clinically and biologically heterogeneous. While various prognostic features have been proposed, none currently impact therapy selection, particularly in older patients, for whom treatment is primarily…
View article: P1152: DEPTH OF METABOLIC RESPONSE AT INTERIM PET AND SURVIVAL OUTCOMES AMONG PATIENTS WITH PRIMARY REFRACTORY OR EARLY RELAPSING DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
P1152: DEPTH OF METABOLIC RESPONSE AT INTERIM PET AND SURVIVAL OUTCOMES AMONG PATIENTS WITH PRIMARY REFRACTORY OR EARLY RELAPSING DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) Open
Topic: 19. Aggressive Non-Hodgkin lymphoma - Clinical Background: Identifying patients with DLBCL at high risk for frontline (1L) treatment failure or early relapse is challenging. Total metabolic tumor volume (TMTV) and maximum standardiz…
View article: Multiomic Analysis Identifies a High-Risk Metabolic and TME Depleted Signature that Predicts Early Clinical Failure in DLBCL
Multiomic Analysis Identifies a High-Risk Metabolic and TME Depleted Signature that Predicts Early Clinical Failure in DLBCL Open
PURPOSE 60-70% of newly diagnosed diffuse large B-cell lymphoma (DLBCL) patients avoid events within 24 months of diagnosis (EFS24) and the remainder have poor outcomes. Recent genetic and molecular classification of DLBCL has advanced our…
View article: Depth of metabolic response at interim PET and survival outcomes among patients with primary refractory or early relapsing diffuse large B‐cell lymphoma (DLBCL)
Depth of metabolic response at interim PET and survival outcomes among patients with primary refractory or early relapsing diffuse large B‐cell lymphoma (DLBCL) Open
Background: Total metabolic tumor volume (TMTV) and maximum standardized uptake value (SUVmax) may improve upon standard 18F-fluorodeoxyglucose positron emission tomography/computed tomography (PET-CT)-based assessment during treatment. We…
View article: Defining Primary Refractory Diffuse Large B‐cell Lymphoma (DLBCL) Based on Survival Outcomes
Defining Primary Refractory Diffuse Large B‐cell Lymphoma (DLBCL) Based on Survival Outcomes Open
Background: DLBCL that fails to achieve a complete response (CR) or relapses early after standard immunochemotherapy (IC, e.g., R-CHOP or similar) is referred to as primary refractory DLBCL (prDLBCL) and has a poor prognosis. Different def…
View article: MARGINAL ZONE LYMPHOMA INTERNATIONAL PROGNOSTIC INDEX (MZL‐IPI): A PROGNOSTIC SCORE FOR THE ENTIRE SPECTRUM OF MARGINAL ZONE LYMPHOMAS. A FIL AND SPORE‐MER STUDY
MARGINAL ZONE LYMPHOMA INTERNATIONAL PROGNOSTIC INDEX (MZL‐IPI): A PROGNOSTIC SCORE FOR THE ENTIRE SPECTRUM OF MARGINAL ZONE LYMPHOMAS. A FIL AND SPORE‐MER STUDY Open
Background: Marginal zone lymphomas (MZL) include extranodal (ENMZL), nodal (NMZL), and splenic (SMZL) subtypes. While MZL subtypes have largely been studied as separate entities, most clinical trials evaluate MZL as a single entity. In th…
View article: Response to COVID-19 Vaccination Post-CAR T Therapy in Patients With Non-Hodgkin Lymphoma and Multiple Myeloma
Response to COVID-19 Vaccination Post-CAR T Therapy in Patients With Non-Hodgkin Lymphoma and Multiple Myeloma Open
View article: Cell of origin is not associated with outcomes of relapsed or refractory diffuse large B cell lymphoma
Cell of origin is not associated with outcomes of relapsed or refractory diffuse large B cell lymphoma Open
Activated B cell (ABC) type diffuse large B cell lymphoma (DLBCL), double hit lymphoma (DHL) and double expressor lymphoma (DEL) have poor outcomes to frontline R‐CHOP but impact of these molecular features on outcomes of relapsed/refracto…
View article: Increasing tissue requirements in lymphoma trials may exclude patients with high-risk disease or worse prognosis
Increasing tissue requirements in lymphoma trials may exclude patients with high-risk disease or worse prognosis Open
An enhanced understanding of the molecular heterogeneity of diffuse large B-cell lymphoma (DLBCL) has opened the door to clinical trials evaluating novel agents with subtype-specific activity. It is an emerging question whether core needle…
View article: Causes of death in low-grade B-cell lymphomas in the rituximab era: a prospective cohort study
Causes of death in low-grade B-cell lymphomas in the rituximab era: a prospective cohort study Open
Low-grade B-cell lymphomas other than follicular and small lymphocytic lymphoma (LGBCL) account for 10% of all B-cell non-Hodgkin lymphomas. Despite improvements in survival outcomes for these patients, little is known about cause of death…
View article: PET2 response associated with survival in newly diagnosed diffuse large B-cell lymphoma: results of two independent prospective cohorts
PET2 response associated with survival in newly diagnosed diffuse large B-cell lymphoma: results of two independent prospective cohorts Open
Studies evaluating Positron Emission Tomography scan after 2 cycles of chemotherapy (PET2) in newly diagnosed diffuse large B cell lymphoma (DLBCL) are heterogeneous in patient characteristics, treatments and have conflicting results. Here…
View article: GM-CSF disruption in CART cells modulates T cell activation and enhances CART cell anti-tumor activity
GM-CSF disruption in CART cells modulates T cell activation and enhances CART cell anti-tumor activity Open
View article: Vaccination History and Risk of Lymphoma and Its Major Subtypes
Vaccination History and Risk of Lymphoma and Its Major Subtypes Open
Background: Vaccinations have been hypothesized to play a role in lymphoma etiology, but there are few studies, mixed results, and limited data on lymphoma subtypes. Herein, we investigate the association of vaccinations with risk of major…
View article: Clinicopathologic Characteristics, Treatment, and Outcomes of Post-transplant Lymphoproliferative Disorders: A Single-institution Experience Using 2017 WHO Diagnostic Criteria
Clinicopathologic Characteristics, Treatment, and Outcomes of Post-transplant Lymphoproliferative Disorders: A Single-institution Experience Using 2017 WHO Diagnostic Criteria Open
The World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues (WHO 2017) included updated criteria for diagnosis and classification of post-transplant lymphoproliferative disorders (PTLDs). This study evalu…